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214MEP50/PRMT5 Reduces Gene Expression by
Histone Arginine Methylation and this Is
Reversed by PKCd/p38d Signaling
Kamalika Saha1, Gautam Adhikary1 and Richard L. Eckert1,2,3,4Protein kinase C d (PKCd) and p38d are key proteins in a cascade that stimulates keratinocyte differentiation. This
cascade activates transcription of involucrin (hINV) and other genes associated with differentiation. Protein
arginine methyltransferase 5 (PRMT5) is an arginine methyltransferase that symmetrically dimethylates arginine
residues. This protein interacts with a cofactor,methylosome protein 50 (MEP50), and symmetrically dimethylates
arginine eight of histone 3 (H3R8me2s) and arginine three of histone 4 (H4R3me2s) to silence gene expression.
We use the hINV gene as a tool to understand the relationship between PKCd/p38d and PRMT5/MEP50 signaling.
MEP50 suppresses hINV mRNA level and promoter activity. This is associated with increased arginine dime-
thylation of hINV gene-associated H3/H4. We further show that the PKCd/p38d keratinocyte differentiation
cascade reduces PRMT5 and MEP50 expression, association with the hINV gene promoter, and H3R8me2s and
H4R2me2s formation. We propose that PRMT5/MEP50-dependent methylation is an epigenetic mechanism that
assists in silencing of hINV expression, and that PKCd signaling activates gene expression by directly activating
transcription and by suppressing PRMT5/MEP50-dependent arginine dimethylation of promoter-associated
histones. This is an example of crosstalk between PKCd/p38d signaling and PRMT5/MEP50 epigenetic silencing.
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Protein kinase C d (PKCd) and p38d are key proteins that
control keratinocyte differentiation andproliferation (Adhikary
et al., 2010; Chew et al., 2011, 2013; Efimova et al., 1998,
2002, 2003, 2004). PKCd activates an MEK3/p38d cascade
that triggers events that enhance keratinocyte differentiation
(Eckert et al., 2003, 2004; Efimova et al., 1998, 2003). This
increases activator protein 1 (AP1), Sp1, and Kruppel-like
transcription factor activity leading to activation of
differentiation-associated gene expression (Crish et al., 1998,
2002, 2006). In particular, involucrin (hINV) gene expression
is increased (Adhikary et al., 2010; Banks et al., 1998, 1999;
Chew et al., 2013; Crish and Eckert, 2008; Crish et al., 1998,
2002, 2006; Han et al., 2012; Welter and Eckert, 1995;
Welter et al., 1995). This regulation is mediated via specific
elements in the hINV promoter distal regulatory region (DRR)
that function both in cultured cells and in vivo (Crish et al.,
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that antagonize this prodifferentiation signaling mechanism.
Modification of arginine side chain guanidine groups is
quantitatively one of the most frequent modifications in cells
(Bedford and Clarke, 2009). Three distinct types of methylated
arginine residues occur in cells. The most prevalent is omega-
NG,NG-asymmetric dimethylarginine (Paik et al., 2007) where
two methyl groups are placed on one of the terminal nitrogen
atoms of the guanidine group to form asymmetric dimethy-
larginine. Other forms include symmetric dimethylated argi-
nine, where one methyl group is placed on each of the
terminal guanidino nitrogens (omega-NG,NG-symmetric
dimethylarginine) and the monomethylated derivative with a
single methyl group on the terminal nitrogen atom (omega-
NG-monomethylarginine) (Paik et al., 2007).
Protein arginine methyltransferase 5 (PRMT5) is an arginine
methyltransferase that symmetrically dimethylates arginine
residues on target proteins in both the cytoplasm and nucleus
(Bedford and Clarke, 2009). Histones H3 and H4 are
important targets. PRMT5 symmetrically dimethylates H3
and H4 as part of an epigenetic mechanism (Molina-Serrano
et al., 2013). Histone H4 is symmetrically dimethylated on
arginine 3 (H4R3me2s), and histone H3 is symmetrically
dimethylated on arginine 8 (H3R8me2s), and this is associ-
ated with silencing of gene expression (Bedford and Clarke,
2009; Fabbrizio et al., 2002; Tae et al., 2011).
Our recent study shows that PRMT5 antagonizes
differentiation-associated signaling and reduces hINV gene
expression (Kanade and Eckert, 2012). PRMT5 acts with
MEP50 to form a complex which stimulates PRMT5 catalytic
activity (Ho et al., 2013; Hosohata et al., 2003). In this study,
we examine the role of MEP50 in mediating this response.
We show that MEP50 suppresses hINV gene expression asuthors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
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activity. This is associated with increased arginine dimethyla-
tionof thehINVgenepromoter.We further show that thePKCd/
p38d keratinocyte differentiation cascade reduces PRMT5 and
MEP50 expression and PRMT5/MEP50 association with the
hINV gene promoter leading to increased promoter activity.
We propose that PRMT5/MEP50 silencing of hINV expression
is an important epigenetic mechanism that suppresses
expression of differentiation-associated genes in the undiffer-
entiated epidermal basal layers.We further propose that loss of
PRMT5/MEP50 activity during differentiation is permissive for
expression of differentiation-associated genes.
RESULTS
MEP50 and PRMT5 form a complex
Our previous study showed that PRMT5 has an important
regulatory role in keratinocytes (Kanade and Eckert, 2012). In
this study, we examine the role of MEP50, a putative PRMT5
cofactor (Bedford and Clarke, 2009; Karkhanis et al., 2011;
Yang and Bedford, 2013), as a regulator of keratinocyte dif-
ferentiation. Recent studies show that MEP50 interacts with
and is necessary for PRMT5 activity (Antonysamy et al.,
2012). We first examined whether a PRMT5/MEP50 com-
plex exists in keratinocytes. Keratinocyte extracts were pre-
pared and immunoprecipitated with anti-MEP50. Figure 1a
shows that PRMT5 coprecipitates with MEP50. Moreover, as
shown in Figure 1b and c, treatment with MEP50-siRNA
partially reduces the MEP50 mRNA level and this is associ-
ated with reduced PRMT5 mRNA expression, and also
reduced MEP50 and PRMT5 protein levels. Conversely,
treatment with PRMT5-siRNA reduces PRMT5 and MEP50
mRNA levels and this is associated with reduced levels of
MEP50 and PRMT5 protein. To further study this regulation,
we expressed PRMT5 or MEP50 and monitored the impact on
the level of the corresponding partner. Figure 1d shows that
overexpression of PRMT5 or MEP50 increases the level,
respectively, of MEP50 and PRMT5. These findings suggest
that MEP50 and PRMT5 are coregulated.
MEP50 suppresses hINV expression
To assess MEP50 function, we examined the impact of
manipulating MEP50 expression on the hINV mRNA level
and promoter activity. Keratinocytes were transfected with an
empty vector or an MEP50 expression vector, and after
24 hours the level of mRNA encoding hINV and filaggrin was
monitored. These genes were selected because both are
markers of terminal keratinocyte differentiation (Eckert et al.,
1997; Presland et al., 1997). We show that expression of
MEP50 reduces the hINV and filaggrin mRNA level (Figure 2a
and b), suggesting that MEP50 acts to suppress
differentiation-associated gene expression. We have previ-
ously identified a -2471/-1 segment of the hINV promoter
that mediates differentiation-appropriate hINV expression in
cell culture and in vivo (Adhikary et al., 2010; Banks et al.,
1998, 1999; Chew et al., 2013; Crish and Eckert, 2008;
Crish et al., 1998, 2002, 2006; Han et al., 2012; Welter
and Eckert, 1995; Welter et al., 1995), and also a region of
the promoter, called the DRR (nucleotides -2473/-2088),
which encodes transcription factor binding elements that are
essential for appropriate differentiation-associated geneexpression (Banks et al., 1998; Crish et al., 1998, 2006).
Transfection of hINV-2473 (full-length promoter) in the
presence of MEP50 suppresses hINV promoter activity
(Figure 2c). Moreover, MEP50 expression suppresses and
MEP50-siRNA increases the activity of a reporter construct
(-2473/-2088) encoding the hINV DRR region (Figure 2d and
e). Maps of the promoter constructs are shown in Figure 3a
and b. The hINV promoter encodes a key AP1 transcription
factor binding site, AP1-5, located within the hINV gene
DRR, that is absolutely required for correct differentiation-
associated expression in cultured keratinocytes and in vivo
(Crish et al., 1993, 1998, 2002, 2006). Figure 3a shows the
hINV(-2473/-2088) and hINV(-2473/-2088)AP1-5m con-
structs, where the DRR region is fused to the minimal hINV
promoter at nucleotide -41. The AP1-5 site is mutated in
hINV(-2473/-2088)AP1-5m. Figure 3b shows promoter maps
indicating hINV-2473, the full-length hINV gene promoter,
and the hINV-241 and hINV-41 truncation constructs (Crish
et al., 1993, 1998, 2002, 2006; Efimova et al., 1998;
Welter and Eckert, 1995). We used these to examine the
effect of mutating the hINV promoter AP1-5 site on MEP50
regulation of hINV promoter activity. Figure 3c shows that the
AP1-5 site mutant, in the context of the DRR, results in a loss
of promoter activity and loss of MEP50-associated suppres-
sion of promoter activity, suggesting that AP1 transcription
factor signaling and the MEP50 epigenetic silencing produce
opposing responses on the hINV promoter.
MEP50 controls histone arginine methylation at the hINV
promoter. We next examined the impact of MEP50 on the
activity of the constructs shown in Figure 3b to identify
promoter regions that are responsive to MEP50. As expected
of a regulatory protein involved in arginine methylation of
histones, MEP50 acts at various sites along the hINV pro-
moter, as it suppresses the activity of hINV-2473, hINV-241,
and hINV-41 (Figure 3d). However, because it is a key reg-
ulatory region (Crish et al., 1998, 2006), we studied the effect
of MEP50 on arginine methylation of histones surrounding
the hINV promoter DRR region. Keratinocytes were electro-
porated with 3 mg of control- or MEP50-siRNA, and after
48 hours, extracts were prepared for chromatin immuno-
precipitation (ChIP) with anti-IgG, anti-PRMT5, or anti-
MEP50. Figure 4a shows that reducing the PRMT5 or
MEP50 level is associated with reduced the binding of
PRMT5 and MEP50 to the hINV promoter DRR region that
encodes the AP1-5 and GC-rich (Sp1) binding sites
(Figure 4a). Moreover, the reduction in the MEP50 level is
associated with reduced H3R8me2s and H4R3me2s forma-
tion (Figure 4b). These findings are consistent with MEP50
control of arginine methylation status at the hINV promoter.
Impact of PKCd/p38d signaling on MEP50 and PRMT5
interaction and activity at the hINV promoter
We previously described a PKCd/p38d mitogen-activated
protein kinase (MAPK) signaling pathway that increases hINV
expression and promoter activity, and expression of other
differentiation-associated genes in keratinocytes (Efimova and
Eckert, 2000; Efimova et al., 1998, 2003, 2004). We asked
whether activation of this cascade suppresses MEP50 level.
Keratinocytes were infected with empty, PKCd-encoding, or
p38d-encoding adenovirus, and after 48 hours, extracts werewww.jidonline.org 215
Figure 1. MEP50 and PRMT5 form a complex in keratinocytes. (a) Freshly isolated foreskin keratinocyte lysates (300 mg) were used for immunoprecipitation
with rabbit IgG or rabbit anti-MEP50, and 10 mg of total extract was electrophoresed. The antibodies for immunoblot are mouse anti-MEP50 and goat anti-
PRMT5. Similar results were obtained in three separate experiments. The upper band (*) in the blot probed with MEP50 is nonspecific. (b, c) Keratinocytes were
electroporated with 3 mg of control-, MEP50-, or PRMT5-siRNA. After 48 hours, RNA was isolated and the MEP50 and PRMT5 mRNA levels were assessed by
qRT-PCR. The values are mean  SEM, n ¼ 3. The asterisks indicate significant differences as determined by Student’s t-test (*P < 0.005). Extracts were also
prepared to assess PRMT5 and MEP50 protein levels. (d) MEP50 or PRMT5 overexpression. KERn were electroporated with 3 mg of control plasmid or plasmids
encoding MEP50 or PRMT5, or MEP50-encoding adenovirus (10 MOI). After 48 hours, protein lysates were prepared for immunoblot with anti-MEP50 and anti-
PRMT5. b-Actin was used as the loading control. Similar results were observed in each of three experiments. KERn, keratinocyte; MEP50, methylosome protein
50; PRMT5, protein arginine methyltransferase 5.
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216prepared to monitor MEP50, PRMT5, H3R8me2s, and
H4R3me2s. Figure 5a shows that PKCd and p38d reduce
intracellular MEP50 and PRMT5 levels and PRMT5/MEP50-
dependent histone modification. Figure 5b and c shows that
this is associated with loss of MEP50 and PRMT5 interaction
with the hINV promoter, and reduced MEP50/PRMT5-
dependent histone modification at the hINV promoter DRR.Journal of Investigative Dermatology (2016), Volume 136Impact of phorbol ester on the MEP50 and PRMT5 level
and interaction and activity at the hINV promoter
12-O-Tetradecanoylphorbol-13-acetate is a known inducer
of keratinocyte differentiation and hINV gene expression.
We wanted to assess whether an inducer of differentiation
would replicate the regulation of MEP50 and PRMT5
observed after the expression of PKCd and p38d. Treatment
Figure 2. MEP50 suppresses involucrin expression. (a, b) KERn were electroporated with the indicated plasmids. After 24 hours, RNAwas isolated and MEP50,
involucrin, and filaggrin mRNA levels were assessed by qRT-PCR. The values are mean  SEM (n ¼ 3). The asterisks indicate a significant difference (P < 0.005).
(c, d) KERn were transfected with 0.5 mg of the indicated involucrin promoter plasmids in the presence of 1 mg of pcDNA3 or pcDNA3-FLAG-MEP50. At 24
hours after transfection, extracts were prepared and assayed for promoter activity. (e) KERn were electroporated with 3 mg of control-siRNA or MEP50-siRNA.
After 48 hours, the cells were re-electroporated with 3 mg of endo-free involucrin promoter. After an additional 24 hours, extracts were prepared and assayed for
promoter activity (luciferase). KERn, keratinocyte; MEP50, methylosome protein 50.
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milliliter for 48 hours suppresses the MEP50 and PRMT5
mRNA level (Figure 6a), and this is associated with a
reduced PRMT5 and MEP50 level (Figure 6b) and an
increased hINV mRNA level (Figure 6c). To examine the
impact of 12-O-tetradecanoylphorbol-13-acetate treatment
on PRMT5 and MEP50 interaction with the hINV promoter
DRR region, we prepared extracts for ChIP analysis.
Figure 6d shows a reduction in PRMT5 and MEP50 associ-
ation with the hINV promoter that is associated with
reduced promoter-associated arginine-dimethylated histone
(Figure 6e).
DISCUSSION
hINV has been extensively studied as a model to understand
the mechanisms that drive gene expression during keratino-
cyte differentiation (Bikle et al., 2001, 2003; Denning
et al., 1995, 2000; Dlugosz et al., 1994; Eckert
et al., 2004). PKCd/p38d MAPK signaling is a keyprodifferentiation/antiproliferation pathway in keratinocytes
(Eckert et al., 2002, 2003). Genetic and inhibitor studies
indicate that PKCd and p38d activities stimulate hINV gene
transcription and increase the hINV mRNA and protein level
(Dashti et al., 2001; Efimova and Eckert, 2000; Efimova et al.,
1998, 2002, 2003, 2004; Kraft et al., 2007). Moreover,
treating keratinocytes with agents that activate this cascade,
including 12-O-tetradecanoylphorbol-13-acetate and cal-
cium, increases hINV gene expression (Adhikary et al., 2005;
Chew et al., 2013; Deucher et al., 2002; Eckert et al., 2004).
This pathway includes PKCd, Ras, MEKK1, and MEK3
and activation results in increased p38d and reduced
ERK1/2 activity (Efimova and Eckert, 2000; Efimova et al.,
1998, 2003, 2004; Kraft et al., 2007). p38d activation
drives nuclear accumulation of AP1 transcription factors that
interact with the AP1-5 transcription factor binding site in
the hINV promoter DRR to increase hINV gene transcription
(Efimova et al., 1998; Welter and Eckert, 1995; Welter
et al., 1995). The DRR also includes an Sp1 (GC-rich)www.jidonline.org 217
Figure 3. MEP50 suppression of hINV
promoter activity. (a, b) Schematic
showing key regulatory elements in
the hINV promoter. hINV(-2473/-
2088) is a construct in which the DRR
(nucleotides -2473/-2088) is linked
to the hINV minimal promoter.
The dashed line indicates the
fusion. hINV(-2473/-2088)AP1-5M is
identical, except that the AP1-5 site
is mutated. hINV-2473 (full-length
promoter), hINV-241, and hINV-41
(minimal promoter) comprise a
truncation series. The functionally
important AP1 (AP1-1 and AP1-5)
sites and GC-rich (Sp1) element
are indicated. The distances are
in nucleotides relative to the
transcription start site. (c, d) KERn
were transfected with 0.5 mg of
hINV-2473, which encodes the full-
length wild-type human involucrin
promoter, or the promoter harboring
a mutant AP1-5 site (AP1-5m), or
truncated promoters (hINV-241,
hINV-41) and 1 mg of pcDNA3 or
pcDNA3-FLAG-MEP50. At 24 hours
after transfection, cell extracts were
prepared and assayed for promoter
activity. The values are mean  SEM,
n ¼ 3. The asterisks indicate a
significant change, P < 0.005. AP1,
activator protein 1; DRR, distal
regulatory region; hINV, involucrin;
KERn, keratinocyte; MEP50,
methylosome protein 50.
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activity (Banks et al., 1998, 1999). Studies in transgenic mice,
wherein the AP1-5 site is inactivated by mutation, reveal
that this site is essential for differentiation-associated
hINV expression in vivo (Crish et al., 1993, 1998, 2000,
2002, 2006).Journal of Investigative Dermatology (2016), Volume 136Epigenetic silencing of hINV gene expression—MEP50
Understanding molecular events that occur at the AP1-5
element is important for understanding control of differen-
tiation. Although substantial knowledge is available
regarding pathways that positively regulate differentiation-
associated gene expression (i.e., differentiation), less is
Figure 4. MEP50 controls histone
arginine methylation at the hINV
promoter. (a, b) KERn were
electroporated with 3 mg of control-
siRNA or MEP50-siRNA. After 48
hours, extracts were prepared for ChIP
analysis. DNA from 1 million cells
was sheared, collected, and 100,000
cell equivalents of DNA were
immunoprecipitated. The primers
include nucleotides -2218/-2055 of
the DRR region of the hINV promoter
region that includes the AP1-5 site.
The values are mean  SEM, n ¼ 3,
and the asterisks indicate significant
difference, P < 0.005. AP1, activator
protein 1; DRR, distal regulatory
region; hINV, involucrin; KERn,
keratinocyte; MEP50, methylosome
protein 50.
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This is important, as suppression of gene expression, in
epidermis, prevents premature activation of differentiation.
Epigenetic mechanisms often inhibit differentiation-
associated gene expression (Gilbert et al., 2004; Saha et al.,
2013), and we have shown that these mechanisms are
important in controlling keratinocyte differentiation
(Choudhury et al., 2011; Eckert et al., 2011; Kanade and
Eckert, 2012). PRMT5 is the major type II arginine methyl-
transferase (Branscombe et al., 2001), and its first identified
biological role was that of a transcriptional repressor
(Fabbrizio et al., 2002). We recently reported that PRMT5 in-
teracts with and antagonizes PKCd/p38d MAPK activation of
hINV gene expression (Kanade and Eckert, 2012).We showedthat PRMT5 interacts with a multiprotein regulatory complex
that includes p38d to antagonize PKCd/p38d signaling and
suppress differentiation (Kanade and Eckert, 2012). However,
PRMT5 also modifies histones and chromatin to arginine
dimethylate histones to silence gene expression (Karkhanis
et al., 2011). PRMT5 acts to symmetrical dimethylate argi-
nine eight of H3 and arginine 3 of histone 4 to form, respec-
tively, H3R8me2s and H4R3me2s, to silence gene expression
(Pal et al., 2004, 2007; Yang and Bedford, 2013). In this
context, PRMT5 interacts with MEP50, which has recently
been shown to form an octamer with PRMT5 including four
PRMT5 and four MEP50 subunits (Antonysamy et al., 2012;
Ho et al., 2013; Hosohata et al., 2003; Kanade and Eckert,
2012). MEP50 is required for optimal PRMT5 activity.www.jidonline.org 219
Figure 5. PKCd/p38d signaling reduces MEP50 and PRMT5 levels and hINV promoter activity. (a) KERn were infected with 10 MOI of tAd5-EV or Ad5-PKCd,
and after 48 hours, extracts were prepared for the detection of PKCd, MEP50, H3R8me2S, and H4R3me2s. b-Actin was used as a loading control. Similar results
were obtained in three different experiments. (b) KERn were infected as above, and after 48 hours, ChIP was performed using the Diagenode Low Cell ChIP Kit
and primers spanning nucleotides -2218/-2055 if the hINV promoter region includes the AP1-5 site. The values are mean  SEM, n ¼ 3. The asterisks indicate
significant difference (P < 0.005). AP1, activator protein 1; ChIP, chromatin immunoprecipitation; hINV, involucrin; KERn, keratinocyte; MEP50, methylosome
protein 50; PKCd, protein kinase C d.
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Figure 6. TPA suppresses MEP50 and PRMT5 levels and activity. (a, b) KERn were treated with 50 ng/ml TPA for 48 hours, RNA was isolated, and MEP50 and
PRMT5 mRNA levels were assessed by qRT-PCR. The values are mean  SEM, n ¼ 3; asterisks indicate a significant difference, P < 0.005. Simultaneously,
protein extracts were prepared from identically treated cultures to detect MEP50, PRMT5, H3R8me2s, and H4R3me2s. Similar results were obtained in three
different experiments. (cee) KERn were treated with 50 ng TPA/ml and after 48 hours, mRNA extracts were isolated for ChIP analysis and detection of MEP50
and PRMT5 interaction and H3R8me2s and H4R3me2s formation at the hINV promoter. Similar results were obtained in three different experiments. The values
are mean  SEM, n ¼ 3. The asterisks indicate significant difference (P < 0.005). (f) Proposed regulatory model—transcriptional activation and epigenetic de-
repression. PKCd activates the indicated p38dMAPK cascade that triggers AP1, KLF4, and Sp1 transcription factor movement to the nucleus that activates hINV
gene expression and other differentiation-related events. The PKCd/p38d cascade also suppresses the PRMT5 and MEP50 level, leading to reduced histone
arginine dimethylation of histone associated with the hINV promoter leading to de-repression of expression. This cascade can be triggered by expression of
PKCd, p38d, or by treatment with prodifferentiation agents (e.g., TPA). AP1, activator protein 1; ChIP, chromatin immunoprecipitation; hINV, involucrin;
H3R8me2s, arginine eight of histone 3; H4R3me2s, arginine three of histone 4; KERn, keratinocyte; MAPK, mitogen-activated protein kinase; MEP50,
methylosome protein 50; PKCd, protein kinase C d; PRMT5, protein arginine methyltransferase 5; TPA, 12-O-tetradecanoylphorbol-13-acetate.
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We show that MEP50 and PRMT5 exist as a complex in
keratinocytes, and that MEP50 and PRMT5 are coregulated
such that a forced change in the MEP50 level results in a
parallel change in the PRMT5 level and vice versa. These
findings are consistent with recent information showing
that PRMT5 and MEP50 form an octamer that requires that
the cell maintain approximately equal amount of each
(Antonysamy et al., 2012; Ratovitski et al., 2006; Rocco et al.,
2006). Translational regulation, dependent on specific
miRNAs, has been described as a mechanism to control the
PRMT5 level (Karkhanis et al., 2011; Yang and Bedford,
2013). However, our studies suggest that regulation of gene
transcription or mRNA stability may also control the PRMT5
and MEP50 level, because knockdown of MEP50 causes a
marked reduction in the PRMT5 mRNA level, and PRMT5
knockdown reduces the MEP50 mRNA level (Figure 1),
suggesting that MEP50 and PRMT5 mutually control the level
of mRNA encoding the other factor. Additional future studies
will be required to understand this mechanism.
MEP50 suppresses hINV expression
Functional studies indicate an inverse relationship between
the MEP50 level and hINV gene promoter activity and the
mRNA level. MEP50 suppresses the transcription of hINV
promoter luciferase reporter plasmids encoding nucleotides
-2218/-2055, -2473/-1, -241/-1, or -41/-1 of the hINV pro-
moter. This suggests that arginine dimethylation of chromatin,
occurring at various regions in the promoter, can reduce gene
expression. This is anticipated, as PRMT5 can impact large
tracks of chromatin within and surrounding a promoter. To
study the details of this regulation, we focused on the DRR
region, located within nucleotides -2218/-2055, which en-
codes key transcription factor binding sites that are required
for hINV gene expression (Banks et al., 1998; Crish et al.,
1993, 1998; Welter et al., 1995). We observed a reduction
in MEP50 interaction with DRR chromatin after MEP50
knockdown. Consistent with an obligatory interaction be-
tween PRMT5 and MEP50, MEP50 knockdown also reduced
PRMT5 levels in chromatin, and these reductions were
associated with reduced H3R8me2s and H4R3me2s forma-
tion. Thus, histone arginine dimethylation is associated with
reduced hINV gene expression and demethylation is required
for increased expression. The idea that PRMT5 and MEP50
act as antidifferentiation and/or prosurvival regulators is
consistent with current reports showing that PRMT5 nega-
tively controls transcription of growth inhibitory genes
(Chang et al., 2010; Gu et al., 2012; Wang et al., 2008).
PKCd/p38d versus PRMT5/MEP50 signaling—a productive
balance
We also show that activation of a classic PKCd/p38d cascade,
which increases differentiation (Eckert et al., 2004; Efimova
et al., 2002, 2003, 2004), reduces MEP50 and PRMT5
levels and PRMT5-dependent chromatin modification. The
reduced PRMT5 and MEP50 level and activity were observed
when PKCd or p38d was overexpressed, or when the activity
of these kinases was stimulated by phorbol ester, a known
inducer of keratinocyte differentiation (Eckert et al., 2004;
Efimova et al., 2002, 2003, 2004). This observation suggests
that prodifferentiation signaling inhibits PRMT5/MEP50Journal of Investigative Dermatology (2016), Volume 136epigenetic silencing as a component of the process that
drives differentiation. We also observed that PRMT5/MEP50
feedback regulates PKCd and p38d activity, suggesting that
a balance between these regulatory mechanisms controls
cell status. For example, MEP50 overexpression reduces
PKCd-Y311 phosphorylation, an indicator of reduced PKCd
activity (not shown). This finding is consistent with our recent
report showing that PRMT5 arginine dimethylates proteins in
the p38d MAPK complex, which is part of the PKCd/p38d
signaling cascade, to reduce p38d phosphorylation and ac-
tivity (Kanade and Eckert, 2012). This suggests that proper
control of keratinocyte fate requires a balance between
PKCd/p38d prodifferentiation signaling and PRMT5/MEP50
antidifferentiation and/or prosurvival signaling. It is inter-
esting that a conventional differentiation stimulus, treatment
with elevated (1.5 mM) calcium chloride, did not suppress
the PRMT5 or MEP50 level, suggesting that different differ-
entiation stimuli may have differing impacts.
Regulation of the PRMT5 level has been extensively studied
at the translational and posttranslation level. An important
study showed that mutant JAK kinase, in myeloproliferative
neoplasms, phosphorylates PRMT5 (Liu et al., 2011) to reduce
PRMT5 association with MEP50, leading to reduced PRMT5
activity, but no change in the PRMT5 level (Liu et al., 2011).
Additional studies show that specific miRNAs control trans-
lation of PRMT5 and MEP50 protein (Yang and Bedford,
2013). Moreover, another study suggests that MEP50 is
phosphorylated by CDK4 and that this leads to increased
PRMT5/MEP50 activity (Aggarwal et al., 2010). Our present
studies suggest a third option—that PRMT5 and MEP50 levels
can be controlled by transcriptional mechanisms or by altered
mRNA stability. We show that stimulation of PKCd/p38d
signaling reduces PRMT5 andMEP50mRNA levels, leading to
reduced production of these proteins, as a mechanism to
reduce PRMT5 activity and arginine methylation of the hINV
promoter (Figure 6f). We have previously shown that a PKCd,
MEKK1, MEK3, p38d cascade increases AP1/Sp1 and KLF4
transcription factor binding to the DRR element to activate
transcription (Eckert et al., 2004; Efimova et al., 1998, 2002,
2003). We now propose that this same pathway acts to sup-
press PRMT5/MEP50 expression, leading to reduced histone
arginine dimethylation of the hINV DRR. It is an interesting
feature that PKCd/MAPK signaling converges via two mech-
anisms, transcriptional activation of hINV gene expression
and inhibition of hINV promoter histone arginine dimethyla-
tion, to increase hINV promoter activity (Figure 6f). We pro-
pose that this may be a general mechanism to regulate
differentiation-associated gene expression in keratinocytes.
MATERIALS AND METHODS
Cell culture, plasmids, and viruses
The human epidermal keratinocytes used in our studies were ob-
tained from foreskin epidermis. Foreskin epidermis, obtained from
newborn infants, was separated from dermis by overnight dispase
treatment. Keratinocytes (KERn) were obtained by trypsin treatment
and maintained in supplemented keratinocyte serum-free medium
(KSFM) (Efimova et al., 2003, 2004). The human hINV promoter
constructswere previously described (Banks et al., 1998;Welter et al.,
1995). The human MEP50-encoding plasmid was constructed
by primer amplification using plasmid p-OTB7-FLAG-MEP50
K Saha et al.
MEP50 and PRMT5 Regulate Differentiation(pOTB7-WDR77, MHS1011-202830316) from Open Biosystems
(Huntsville, AL) as a template. The primers used for amplification of
FLAG-MEP50 (BamHI/NotI fragment) were 50-GATC GGA TCC ATG
GAC TACAAGGACGACGACGACAAG ATG CGGAAGGAA ACC
CCA and 50-GATCGCGGCCGCC TAC TCAGTA ACACTTGCAGG.
The ATG start codon is bold and the FLAG epitope is underlined.
The product was then cloned into pcDNA3 to get pcDNA3-FLAG-
MEP50. Adenoviruses encoding HA-p38d, PKCd, and empty
control virus (tAd5-HA-p38d, Ad5-PKCd, Ad5-FLAG-p38d, and Ad5-
EV) were prepared by propagation in HEK293 cells and cesium
gradient purification (Chew et al., 2011). The MEP50-FLAG-His tag-
encoding adenovirus was from Vigene Biosciences (Rockville, MD;
#VH804847). Culture of human foreskin keratinocytes was approved
as an exempt study by the University of Maryland Human Subjects
Institutional Review Board.
Promoter luciferase assay
FUGENE 6 (4.5 ml) was diluted in 95.5 ml KSFM and the mixture was
incubated at room temperature for 15 minutes. Next, the human
hINV promoter reporter plasmid (0.5 mg) and 1 mg of pcDNA3 or
pcDNA3-FLAG-MEP50 were added to the mixture followed by a
20-minute incubation. This mixture was added to 2 ml of KSFM in
dishes containing 50% confluent KERn cultures. After 24 hours, cell
lysates were processed for a luciferase activity assay (Adhikary et al.,
2010).
Keratinocyte electroporation
Our studies used the AMAXA electroporator and VPD-1002 nucle-
ofection kit (Lonza Inc., Cologne, Germany) for keratinocyte elec-
troporation. KERn were harvested with trypsin and replated 1 day
before electroporation. After an additional 24 hours, the cells were
harvested with trypsin and 1 million cells were used per electro-
poration. The cells were washed with 1 ml of PBS and suspended in
100 ml of keratinocyte nucleofection solution containing 3 mg of
control-, MEP50-, or PRMT5-siRNA. The mixture was mixed by
gentle pipetting and transferred to the electroporation cuvette. The T-
018 setting was used for electroporation. This was followed with the
addition of warm KSFM (500 ml) and the mixture was then trans-
ferred to a 55 cm2 dish containing 10 ml of KSFM. The cells were
maintained for various time points before the extracts were prepared
for mRNA or protein analysis. This method achieves electroporation
efficiencies of greater than 90% (Adhikary et al., 2010).
Chromatin immunoprecipitation assay
ChIP assays were performed using the Diagenode Low Cell ChIP
assay kit (Denville, NJ; C01010073: kch-maglow-G48). Keratinocyte
(0.5  106) cells were infected with 15 MOI of empty adenovirus or
adenoviruses encoding HA-p38d or PKCd. After 48 hours, the cells
were harvested and 1  106 cells per group were used for sonicat-
ion. Extract equivalent to 100,000 cells was used for immunopre-
cipitation per sample. MEP50, PRMT5, H4R3Me2s, and H3R8me2s
antibodies were used for ChIP analysis and binding to the DRR of the
hINV promoter was detected by qRT-PCR using sequence-specific
primers and the LightCycler 480 SYBR Green I master mix. The
primers used to detect the DRR of the hINV promoter (nucleotides
-2218/-2055), encoding the AP1-5/Sp1 binding sites, were 50-TCA
GCT GTA TCC ACT GCC CTC TTT (forward) and 50-TCA CAC CGG
TCT TAT GGG TTA GCA (reverse).
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